Increased lithium levels in water could increase the risk of autism.

Published Date: 05 Apr 2023

A new study led by a UCLA Health researcher found that pregnant women had a slightly increased risk of having children with autism spectrum disorder if the household tap water had higher lithium levels.

Read Full News

Latest News

Clene Submits NDA Seeking Accelerated Approval for ALS Drug Marco Meglio

Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years of evolving FDA guidance.

Amyloid Vaccine AV-1959R Generates Antibodies in All Phase 1 Recipients Louie Pasculli

In a 16-person placebo-controlled trial, every cognitively unimpaired adult given AV-1959R developed anti-amyloid-beta antibodies, while placebo recipients stayed at baseline.

Diazepam Nasal Spray Terminates Most Pediatric Status Epilepticus Episodes in Seizure Clusters, Post Hoc Analysis Shows Isabella Ciccone, MPH

Newly presented post hoc analyses examined diazepam nasal spray for status epilepticus in seizure clusters and intervals between clusters in children, alongside real-world data on rescue medication prescribing.

Real-World Data Back Stiripentol’s Effect on Seizures in Dravet Syndrome Marco Meglio

A retrospective 10-center U.S. study found stiripentol reduced convulsive seizure frequency, status epilepticus episodes, and emergency health care use in patients with Dravet syndrome.

Decade of OPERA Data Supports Early Ocrelizumab Treatment Initiation in Relapsing Multiple Sclerosis Isabella Ciccone, MPH

A newly published 10-year analysis of the OPERA I and II trials reported that starting ocrelizumab 2 years earlier was associated with less disability accrual in relapsing MS, with no new safety signals.

This Week on NeurologyLive® — October 19, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Todays Updates

AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women

AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women

CHEST 2026: Day 3 Recap — 6 Headlines to Know

CHEST 2026: Day 3 Recap — 6 Headlines to Know

What the Next Accelerated TMS Trial Should Test, With Jonathan Downar, MD Jonathan Downar, MD, PhD

Downar outlines the randomized trial needed to confirm optimal TMS dosing and addresses a safety ceiling on total pulses.

NeuroVoices: Bruce Bebo, PhD, on Big Bets for Breakthroughs and the Campaign to End MS Bruce Bebo, PhD, Isabella Ciccone, MPH

The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.

Divozilimab Cuts Relapse Risk at 1 Year in Phase 3 AQUARELLE Trial of NMOSD Marco Meglio

One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.

Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis Marco Meglio

Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.

FDA Grants Fast Track to AV-1959R for Alzheimer Prevention Matt Hoffman

Fast Track status covers AV-1959R, an investigational amyloid-beta vaccine, for preventing Alzheimer disease in cognitively unimpaired adults with amyloid pathology.

Todays Updates

AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women

AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women

CHEST 2026: Day 3 Recap — 6 Headlines to Know

CHEST 2026: Day 3 Recap — 6 Headlines to Know

What the Next Accelerated TMS Trial Should Test, With Jonathan Downar, MD Jonathan Downar, MD, PhD

Downar outlines the randomized trial needed to confirm optimal TMS dosing and addresses a safety ceiling on total pulses.

NeuroVoices: Bruce Bebo, PhD, on Big Bets for Breakthroughs and the Campaign to End MS Bruce Bebo, PhD, Isabella Ciccone, MPH

The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.

Divozilimab Cuts Relapse Risk at 1 Year in Phase 3 AQUARELLE Trial of NMOSD Marco Meglio

One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.

Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis Marco Meglio

Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.

FDA Grants Fast Track to AV-1959R for Alzheimer Prevention Matt Hoffman

Fast Track status covers AV-1959R, an investigational amyloid-beta vaccine, for preventing Alzheimer disease in cognitively unimpaired adults with amyloid pathology.

Latest News

Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years of evolving FDA guidance.

In a 16-person placebo-controlled trial, every cognitively unimpaired adult given AV-1959R developed anti-amyloid-beta antibodies, while placebo recipients stayed at baseline.

Newly presented post hoc analyses examined diazepam nasal spray for status epilepticus in seizure clusters and intervals between clusters in children, alongside real-world data on rescue medication prescribing.

A retrospective 10-center U.S. study found stiripentol reduced convulsive seizure frequency, status epilepticus episodes, and emergency health care use in patients with Dravet syndrome.

A newly published 10-year analysis of the OPERA I and II trials reported that starting ocrelizumab 2 years earlier was associated with less disability accrual in relapsing MS, with no new safety signals.

Here's some of what is coming soon to NeurologyLive® this week.

News All Time

TSHA-102 Produces Multidomain Functional Gains in Rett Syndrome Matt Hoffman

All 10 REVEAL Part A participants gained or regained at least 1 developmental milestone after a single intrathecal TSHA-102 dose, with no treatment-related SAEs reported.

Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial Louie Pasculli

Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

New Phase 1 Study Tests Intrathecal Gene Therapy Agent INS1201 in Duchenne Muscular Dystrophy Marco Meglio

The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.

MDS Congress 2026: Late-Breaking Data Snapshot Marco Meglio

A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.

ELEVIDYS Shows Sustained Functional Differences vs External Controls in Older Ambulatory Duchenne Patients Louie Pasculli

New analyses found differences in functional outcomes over 2 years among patients aged 8 to 12 years treated with delandistrogene moxeparvovec, while separate findings characterized micro-dystrophin expression in children younger than 3 years.

Dompé Begins Phase 2 Trial Testing Intranasal Nerve Growth Factor for Cerebral Palsy Marco Meglio

The Galassia trial will evaluate the safety and tolerability of intranasal cenegermin in about 60 children with spastic cerebral palsy across Italy.

Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression Isabella Ciccone, MPH

A post hoc analysis of the phase 2/3 NPC002 trial presented at CNS 2026 showed that the benefit of arimoclomol plus miglustat in Niemann-Pick disease type C emerged as early as 3 months after treatment initiation.

Telitacicept Shows Deepening, Durable Response in Myasthenia Gravis Marco Meglio

New 48-week phase 3 data show many patients with generalized myasthenia gravis reached minimal symptom expression on telitacicept, and most who did sustained it.

NeuroVoices: Ali Habib, MD, on Cemdisiran and the Phase 3 NIMBLE Trial Data in Myasthenia Gravis Marco Meglio, Ali Habib, MD

The professor of neurology and program director of Neuromuscular Medicine at UC Irvine, discusses phase 3 NIMBLE trial findings for cemdisiran in generalized myasthenia gravis, including its novel siRNA mechanism, efficacy, and hospitalization data.

Fenfluramine Shows Consistent Seizure Reduction Across Age Groups in CDKL5 Deficiency Disorder Isabella Ciccone, MPH

An analysis of the phase 3 GEMZ trial presented at CNS 2026 showed that fenfluramine produced comparable seizure reductions and safety outcomes in children and adults with CDKL5 deficiency disorder.

This Week on NeurologyLive® — October 12, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

NeurologyLive® Brain Games: October 11, 2026 Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent therapeutic advances in MS!

Individualizing Advanced Therapies in Parkinson Disease: Hubert Fernandez, MD Hubert Fernandez, MD, Louie Pasculli

The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Phase 4 THRIVE Data Highlights Eptinezumab’s Impact on Migraine After Prior CGRP Failure Marco Meglio

Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.

Recommended News For You

A large study found that monolayers were superior in detecting cancer.

Products for Intimate Care and Cancer; Boost for Colorectal Cancer Stool Tests; Ultrasonic Biopsy?

Single-dose radiation before surgery can eradicate breast cancer

Annual whole-body, low-dose CT aids management of smoldering multiple myeloma

The use of biomarkers in the treatment of breast lumps is at a crossroads.

High CLL Remission Seen With First-Line Triplet Regimen

In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.

Recommended Articles For You

Exposure Modeling for Bispecific Antibodies: Scientific Foundations and Clinical Implications 

Robotic Intratumoral Resection for Organ Preservation: Current Evidence and Clinical Implications 

Revolutionizing Cancer Treatment: Harnessing the Power of AI in Histopathology 

Precision Oncology: How Personalized Medicine is Transforming Cancer Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.

2.

Why alarm is easing over a rise in pancreatic cancer among the young

3.

A protein with new anticancer activity has been identified

4.

Resection for Early Liver Cancer Tied to Improved Survival.

5.

One CAR T-Cell Therapy for Multiple Myeloma Tops Another in Propensity Matched Study

1.

Age-Related Changes in Platelet Reactivity: Mechanisms, Clinical Implications, and Management Strategies

2.

Extracellular Vesicle Markers of Platelet Activation: Clinical Relevance and Emerging Insights

3.

Anesthetic Techniques and Strategies in Cancer Surgery: Unveiling the Impact on Oncological Outcomes

4.

Unlocking the Potential of Lymphocytes: Exploring the Role of These Immune System Cells

5.

Cancer Vaccines in Solid Tumors: Current Landscape, Mechanisms, and Clinical Implications

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

2.

Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion

3.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion

4.

Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites

5.

First Line Combination Therapy- The Overall Survival Data in NSCLC Patients


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot